New Haven-based biotech startup Bexorg is developing a platform combining perfusion of whole human and animal brains with artificial intelligence to improve drug discovery for central nervous system (CNS) disorders. The company’s approach involves restoring cellular and molecular activity in donated human brains post-mortem in order to generate clinically predictive human-brain datasets that can train AI models.
Venture Portfolio
Encapsulate
Encapsulate
Invea Therapeutics, Inc.
Invea Therapeutics, Inc.

